Reformulary 2019 Year in Review
From plan sustainability, including high savings and a low inflation rate, to new and pipeline drug reviews (185 of them!), to extensive data analysis and a suite of medical cannabis tools, we continue to make a remarkable difference. “Making Sense of Medicine” for Canadians and organizations is what we do best.
Click the image below to view the full 2019 Year in Review.